It's a sunny day, the birds are singing, and the FTSE 100 has finally broken the 7,000 barrier. (Sure, there's likely to be a Greek exit from the euro in due course, but in the long term even that will be a good thing.
The pharmaceuticals industry is recovering pretty well from the �patent cliff� problems when a number of key drugs lost their protection in recent years, and though there's increasing competition from generic drugs, our two big FTSE 100 players are ...
April brings our new 2015 ISA allowances, with a modest rise from last year's �15,000 to �15,240. At the moment, the very best cash ISAs around would earn you about �240 in interest, and you should easily be able to beat that with shares.
The prescription data by Symphony Health, complied by Bloomberg analysts, Michael Shah and Sam Fazeli, shows impressive growth in sales of the drugs manufactured by US pharmaceutical giants including Pfizer Inc. (NYSE:PFE), Eli Lilly & Co.